Technology ID
TAB-3740
Composition and Methods for Modulation of Thyrotropin Releasing Hormone for the Treatment of Cancer-related Fatigue
E-Numbers
E-088-2017-0
Lead Inventor
Padia, Janak (Primetime Life Sciences, LLC)
Co-Inventors
Gershengorn, Marvin (NIDDK)
Applications
Therapeutics
Therapeutic Areas
Oncology
Lead IC
NIDDK
ICs
NIDDK
This technology includes a series of small molecule TRHR agonists for the treatment of cancer-related fatigue. In particular, PTLS-04 and PTLS-11 have shown excellent TRHR agonist activities in mouse and human cells and have improved metabolic profile compared to TRI I and taltirelin. Additional work is being done to further optimize the series by designing and synthesizing additional compounds.
Commercial Applications
Treatment of cancer-related fatigue.
Competitive Advantages
First-in-class medication for cancer-related fatigue, which currently has no effective treatment.
Licensing Contact: